share_log

BioLife Solutions (NASDAQ:BLFS) Shares Gap Down to $24.67

BioLife Solutions (NASDAQ:BLFS) Shares Gap Down to $24.67

生物生命解决方案公司(纳斯达克：BLFS)股价下跌至24.67美元
Financial News Live ·  2022/09/21 12:21

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) gapped down before the market opened on Wednesday . The stock had previously closed at $24.67, but opened at $24.12. BioLife Solutions shares last traded at $23.98, with a volume of 128 shares traded.

周三开盘前，生物生命解决方案公司(纳斯达克代码：BLFS-GET Rating)的股价大幅下挫。该股此前收盘报24.67美元，开盘报24.12美元。BioLife Solutions的股票尾盘报23.98美元，总成交量为128股。

Wall Street Analyst Weigh In

华尔街分析师也加入进来

Separately, Cowen reduced their price objective on BioLife Solutions to $29.00 in a research report on Monday, August 15th. One investment analyst has rated the stock with a sell rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $31.25.

另外，考恩在8月15日星期一的一份研究报告中将他们对BioLife Solutions的目标价格下调至29.00美元。一名投资分析师对该股的评级为卖出，三名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据，该公司目前的平均评级为“中等买入”，平均目标价为31.25美元。

Get
到达
BioLife Solutions
生物生命解决方案
alerts:
警报：

BioLife Solutions Stock Performance

BioLife解决方案股票表现

The company has a fifty day simple moving average of $21.91 and a 200 day simple moving average of $18.43. The company has a current ratio of 3.55, a quick ratio of 2.54 and a debt-to-equity ratio of 0.02.

该公司的50日简单移动均线切入位为21.91美元，200日简单移动均线切入位为18.43美元。该公司的流动比率为3.55，速动比率为2.54，债务权益比率为0.02。

Insiders Place Their Bets

内部人士下注

In other BioLife Solutions news, COO Greef Roderick De sold 9,158 shares of BioLife Solutions stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $15.79, for a total transaction of $144,604.82. Following the transaction, the chief operating officer now directly owns 124,458 shares of the company's stock, valued at approximately $1,965,191.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
在BioLife Solutions的其他新闻中，首席运营官Greef Roderick de在一笔日期为7月12日(星期二)的交易中出售了BioLife Solutions的9,158股票。该股以15.79美元的平均价格出售，总成交金额为144,604.82美元。交易完成后，首席运营官现在直接持有该公司124,458股股票，价值约1,965,191.82美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过
this link
这个环节
. In other news, CRO Marcus Schulz sold 4,600 shares of the business's stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $20.03, for a total value of $92,138.00. Following the transaction, the executive now directly owns 36,218 shares of the company's stock, valued at approximately $725,446.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
。在其他新闻方面，CRO马库斯·舒尔茨在8月3日星期三的交易中出售了4600股该公司的股票。股票以20.03美元的平均价格出售，总价值为92,138.00美元。交易完成后，这位高管现在直接持有该公司36,218股股票，价值约725,446.54美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过
the SEC website
美国证券交易委员会网站
. Also, COO Greef Roderick De sold 9,158 shares of the business's stock in a transaction dated Tuesday, July 12th. The shares were sold at an average price of $15.79, for a total value of $144,604.82. Following the completion of the transaction, the chief operating officer now directly owns 124,458 shares in the company, valued at $1,965,191.82. The disclosure for this sale can be found
。此外，首席运营官格里夫·罗德里克·德在日期为7月12日(星期二)的交易中出售了9,158股该公司股票。这些股票的平均价格为15.79美元，总价值为144,604.82美元。交易完成后，首席运营官现在直接拥有该公司124,458股，价值1,965,191.82美元。关于这次销售的披露可以找到
here
这里
. In the last three months, insiders have sold 18,401 shares of company stock valued at $313,764. 3.30% of the stock is currently owned by company insiders.
。在过去的三个月里，内部人士已经出售了18,401股公司股票，价值313,764美元。3.30%的股份目前由公司内部人士持有。

Institutional Inflows and Outflows

机构资金流入和流出

A number of hedge funds and other institutional investors have recently made changes to their positions in BLFS. BlackRock Inc. raised its stake in BioLife Solutions by 1.6% during the 1st quarter. BlackRock Inc. now owns 3,712,680 shares of the medical equipment provider's stock worth $84,390,000 after buying an additional 57,623 shares during the period. Vanguard Group Inc. increased its holdings in BioLife Solutions by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 2,201,602 shares of the medical equipment provider's stock worth $50,043,000 after purchasing an additional 54,344 shares in the last quarter. Millennium Management LLC increased its holdings in BioLife Solutions by 45.3% during the 2nd quarter. Millennium Management LLC now owns 1,560,137 shares of the medical equipment provider's stock worth $21,545,000 after purchasing an additional 486,631 shares in the last quarter. Marshall Wace LLP increased its holdings in BioLife Solutions by 4.2% during the 4th quarter. Marshall Wace LLP now owns 1,346,746 shares of the medical equipment provider's stock worth $50,193,000 after purchasing an additional 54,502 shares in the last quarter. Finally, State Street Corp increased its holdings in BioLife Solutions by 26.1% during the 2nd quarter. State Street Corp now owns 1,270,364 shares of the medical equipment provider's stock worth $17,544,000 after purchasing an additional 263,021 shares in the last quarter. 86.69% of the stock is owned by institutional investors and hedge funds.

一些对冲基金和其他机构投资者最近改变了他们在BLFS的头寸。今年第一季度，贝莱德股份有限公司将其在BioLife Solutions的持股比例提高了1.6%。贝莱德股份有限公司目前持有这家医疗设备供应商3,712,680股股票，价值84,390,000美元，在此期间又购买了57,623股。先锋集团在第一季度增持了2.5%的BioLife Solutions股份。先锋集团(Vanguard Group Inc.)在上个季度增持了54,344股后，现在持有这家医疗设备供应商价值50,043,000美元的股票2,201,602股。千禧管理公司在第二季度增持了生物生命解决方案公司45.3%的股份。Millennium Management LLC现在拥有这家医疗设备提供商1,560,137股票，价值21,545,000美元，上个季度又购买了486,631股票。马歇尔·华斯有限责任公司在第四季度增持了4.2%的BioLife Solutions股份。马歇尔·华斯有限责任公司在上个季度购买了54,502股后，现在拥有这家医疗设备提供商1,346,746股股票，价值50,193,000美元。最后，道富银行在第二季度增持了26.1%的BioLife Solutions股份。道富集团目前持有这家医疗设备提供商1,270,364股股票，价值17,544,000美元，上一季度又购买了263,021股。86.69%的股票由机构投资者和对冲基金持有。

BioLife Solutions Company Profile

BioLife Solutions公司简介

(Get Rating)

(获取评级)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

BioLife Solutions，Inc.为美国、加拿大、欧洲、中东、非洲和国际上的细胞和基因治疗行业开发、制造和提供生物生产工具和服务。该公司的产品用于基础和应用研究，以及基于生物的疗法的商业制造。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
  • General Mills: Superior Returns With Less Volatility
  • 3 Defensive Stocks With 60-Year Dividend Hike Streaks
  • 3 Airline Stocks Stuck in a Holding Pattern
  • Roku Stock is Down but Not Out
  • If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
  • 免费获取StockNews.com关于BioLife解决方案的研究报告(BLFS)
  • 通用磨坊：波动性更小、回报更高
  • 连续60年提高股息的3只防御性股票
  • 3家航空公司股票陷入持有格局
  • Roku股票下跌，但并未出局
  • 如果你渴望价值，那就尝尝露丝的好客之道吧

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

每日收到有关BioLife解决方案的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioLife Solutions和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发